Do we need biologic agents in preoperative systemic therapy of liver metastases?

Keyphrases

• Liver Metastasis 100%
• Biological Agents 100%
• Preoperative Systemic Therapy 100%
• Chemotherapy 66%
• Long-term Survival 66%
• Metastatic Disease 66%
• Surgical Resection 33%
• Patient Management 33%
• Chemotherapy Agents 33%
• Initial Diagnosis 33%
• Metastasis 33%
• Poor Prognosis 33%
• Response Rate 33%
• Cetuximab 33%
• Survival Benefit 33%
• Bevacizumab 33%
• Metastatic Colorectal Cancer (mCRC) 33%
• Preoperative Chemotherapy 33%
• Meaningful Improvement 33%
• Colorectal Liver Metastases 33%
• New Biologics 33%
• Unresectable Liver Metastases 33%
• Initially Unresectable 33%

Medicine and Dentistry

• Biological Product 100%
• Liver Metastasis 100%
• Preoperative Systemic Therapy 100%
• Metastatic Carcinoma 75%
• Long Term Survival 50%
• Recurrent Disease 25%
• Cetuximab 25%
• Bevacizumab 25%
• Metastatic Colorectal Cancer 25%
• Colorectal Carcinoma 25%
• Preoperative Chemotherapy 25%

Nursing and Health Professions

• Biological Product 100%
• Liver Metastasis 100%
• Systemic Therapy 100%
• Long Term Survival 50%
• Recurrent Disease 25%
• Preoperative Chemotherapy 25%
• Metastatic Colorectal Cancer 25%
• Cetuximab 25%
• Colorectal Carcinoma 25%
• Bevacizumab 25%